Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | E-SYNC T cells |
Synonyms | |
Therapy Description |
E-SYNC T cells are autologous T cells engineered to express a modified Notch receptor that binds to EGFRvIII expressed on tumor cells and induces the expression of an anti-EphA2 and anti-IL13Ra2 chimeric antigen receptor (CAR), which potentially leads to selective killing of tumor cells expressing EphA2 or IL13Ra2 (PMID: 33910979, NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
E-SYNC T cells | Anti-EGFRvIII synNotch Receptor-induced Anti-EphA2/IL-13Ralpha2 CAR-T Cells | E-SYNC T cells are autologous T cells engineered to express a modified Notch receptor that binds to EGFRvIII expressed on tumor cells and induces the expression of an anti-EphA2 and anti-IL13Ra2 chimeric antigen receptor (CAR), which potentially leads to selective killing of tumor cells expressing EphA2 or IL13Ra2 (PMID: 33910979, NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06186401 | Phase I | E-SYNC T cells Cyclophosphamide + Fludarabine | Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells | Recruiting | USA | 0 |